C WorldWide Group Holding A S cut its position in shares of Clovis Oncology Inc (NASDAQ:CLVS) by 19.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 169,700 shares of the biopharmaceutical company’s stock after selling 40,927 shares during the period. C WorldWide Group Holding A S’s holdings in Clovis Oncology were worth $11,540,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. KBC Group NV raised its position in Clovis Oncology by 40.2% during the 4th quarter. KBC Group NV now owns 57,012 shares of the biopharmaceutical company’s stock valued at $3,877,000 after purchasing an additional 16,343 shares in the last quarter. Swiss National Bank raised its position in Clovis Oncology by 3.4% during the 4th quarter. Swiss National Bank now owns 79,050 shares of the biopharmaceutical company’s stock valued at $5,375,000 after purchasing an additional 2,600 shares in the last quarter. California Public Employees Retirement System raised its position in shares of Clovis Oncology by 191.1% in the 4th quarter. California Public Employees Retirement System now owns 97,184 shares of the biopharmaceutical company’s stock worth $6,609,000 after acquiring an additional 63,800 shares in the last quarter. Teacher Retirement System of Texas raised its position in shares of Clovis Oncology by 311.8% in the 4th quarter. Teacher Retirement System of Texas now owns 15,644 shares of the biopharmaceutical company’s stock worth $1,064,000 after acquiring an additional 11,845 shares in the last quarter. Finally, Alps Advisors Inc. bought a new position in shares of Clovis Oncology in the 4th quarter worth $3,693,000.

In related news, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $64.97, for a total transaction of $292,365.00. Following the transaction, the director now directly owns 21,118 shares in the company, valued at approximately $1,372,036.46. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $59.16, for a total value of $177,480.00. Following the transaction, the insider now owns 183,571 shares in the company, valued at $10,860,060.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,000 shares of company stock worth $1,123,425. 12.50% of the stock is owned by company insiders.

Clovis Oncology Inc (CLVS) opened at $50.92 on Friday. Clovis Oncology Inc has a one year low of $45.42 and a one year high of $99.45. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.16 and a current ratio of 3.19. The firm has a market capitalization of $2,540.00, a price-to-earnings ratio of -6.15 and a beta of 1.05.

Several research firms have recently commented on CLVS. BidaskClub lowered Clovis Oncology from a “sell” rating to a “strong sell” rating in a research report on Friday. Credit Suisse Group set a $86.00 price target on Clovis Oncology and gave the stock a “buy” rating in a research report on Thursday, January 18th. They noted that the move was a valuation call. Zacks Investment Research lowered Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Clovis Oncology in a research report on Thursday, January 11th. Finally, ValuEngine raised Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $90.43.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/02/10/clovis-oncology-inc-clvs-shares-sold-by-c-worldwide-group-holding-a-s.html.

Clovis Oncology Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.